Skip to main content

Stryker Value Stock - Dividend - Research Selection

Stryker

ISIN: US8636671013 , WKN: 864952

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Dividend Champion, Contender, And Challenger Highlights: Week Of September 28

2025-09-26
Read the latest dividend updates for Dividend Champions, Contenders, and Challengers. Track changes, ex-dividend, and pay dates.

Regenerative Drugs Market Review 2020-2024 and Forecast 2025-2030: A $29 Billion Opportunity Led by Baxter International, Stryker Corporation and Medtronic

2025-09-25
The regenerative drugs market offers significant opportunities in cell-based therapies and organ regeneration, addressing diverse medical fields like cardiovascular and neurology. Key players drive innovation, with Europe leading in cell therapies. Growing global demand and investment highlight potential for healthcare transformation. Global Regenerative Drugs Market Global Regenerative Drugs Market Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Regenerative Drugs Market - Forecasts from 2025 t

There's A Lot To Like About Stryker's (NYSE:SYK) Upcoming US$0.84 Dividend

2025-09-25
Stryker Corporation ( NYSE:SYK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business...

Craniomaxillofacial Devices Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034

2025-09-25
Growth is driven by increased facial injuries from accidents and sports, and congenital deformities in children. Advancements in biocompatible materials and imaging technologies facilitate precise, minimally invasive surgeries. The U.S. market, worth USD 794.6 million in 2024, benefits from high accident rates and innovations in medical devices. Key players, including Medtronic and Stryker, are enhancing portfolios with new technologies, contributing to the market's expansion. Craniomaxillofacia

Single Use Surgical Instruments Market - Global Forecast to 2030 | Single-Use Surgical Instruments Market to Hit USD 7.80 Billion by 2030, Driven by ASCs Demand

2025-09-25
Increasing demand from outpatient and ambulatory surgical centers (ASCs) is driving market growth, as these facilities require efficient, sterile, and cost-effective solutions. Single-use instruments eliminate reprocessing costs and reduce cross-contamination risks, making them ideal for ASCs. Key players include Ethicon, Medtronic, BD, B. Braun, and Stryker. The market offers opportunities due to emerging healthcare infrastructure and challenges with environmental sustainability. Global Single

Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures

2025-09-24
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.

Siemens' AI and Robotics Push Could Be a Game Changer for Siemens (XTRA:SIE)

2025-09-24
Siemens Healthineers and Stryker recently announced a partnership to co-develop robotic systems for neurovascular procedures, aiming to enhance precision and efficiency in stroke and aneurysm care, while Siemens and Merck have agreed to accelerate digital transformation in life sciences by integrating AI and automation into drug discovery and manufacturing. These collaborations highlight Siemens’ increasing emphasis on advanced digital healthcare ecosystems and its intent to shape the future...

Stryker Corp. stock underperforms Tuesday when compared to competitors

2025-09-23
Stryker Corp. stock underperforms Tuesday when compared to competitors

Partnership between Siemens Healthineers and Stryker aims to redefine neurovascular intervention with robotics

2025-09-23
The sector of robotic-assisted neurovascular intervention represents an emerging frontier in cerebrovascular treatment.

ISRG SP Platform's Expansion in Korea and Europe Gains Traction

2025-09-23
Intuitive Surgical's SP platform gains momentum with 112% growth in Korea and steady European uptake, highlighting global adoption despite regional headwinds.